Standard Chem & Pharm Co Ltd - Strategy, SWOT and Corporate Finance Report
SummaryStandard Chem & Pharm Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Standard Chem & Pharm Co Ltd (SCP) manufactures and markets pharmaceutical and healthcare products. The company's product offerings include pharmaceuticals, supplements, and API. SCP's drug delivery platforms include osmotic-controlled release oral system, skin and mucous membrane drugs pulsatile controlled release delivery, micro-encapsulation and lyophilization. SCP develops new products through its R&D facility, Standard Pharmaceutical Research Institute. The company provides out-licensing and in-licensing services, apart from services and partnership opportunities to government agencies, research institutes, and biotechnology firms to commercialize niche products in the global market. The company has business presence in Taiwan, China, Vietnam, Singapore, Thailand, South Korea, Malaysia, the Philippines and the US. SCP is headquartered in Tainan, Sinying District, Taiwan.
Scope
- Detailed information on Standard Chem & Pharm Co Ltd required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Standard Chem & Pharm Co Ltd in the form of a SWOT analysis
- An in-depth view of the business model of Standard Chem & Pharm Co Ltd including a breakdown and examination of key business segments
- Intelligence on Standard Chem & Pharm Co Ltd's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Standard Chem & Pharm Co Ltd, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons To Buy
- Gain understanding of Standard Chem & Pharm Co Ltd and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Standard Chem & Pharm Co Ltd as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Standard Chem & Pharm Co Ltd's business structure, strategy and prospects.
Astellas Pharma is engaged in the development, research, manufacture, and sale of pharmaceuticals. Co. operates its operation in Japan, Americas, Europe, and Asia/Oceania. Co.'s principal product for the global market include "Xtandi" a therapeutic agent for prostatic cancer, "Eligard" a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of prostate cancer,"Prograf" an immunosuppressant used to prevent rejection in organ transplants, "Vesicare" a treatment for overactive bladder, "Harnal ( "Omnic" in the U.S. and Europe)" an 1 blocking agent for prostatic and urethral smooth muscle, and "Fungurad ("Mycamine" in the U.S. and Europe)" a candin-type antifungal agent.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.